<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979121</url>
  </required_header>
  <id_info>
    <org_study_id>670</org_study_id>
    <secondary_id>N01HR056179</secondary_id>
    <nct_id>NCT00979121</nct_id>
  </id_info>
  <brief_title>Statins for Acutely Injured Lungs From Sepsis</brief_title>
  <acronym>SAILS</acronym>
  <official_title>Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: assess the efficacy and safety of oral rosuvastatin in patients with
      sepsis-induced Acute Lung Injury (ALI).

      Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) involves extensive
      inflammation in the lungs that can lead to rapid respiratory failure. These conditions are
      most commonly caused by pneumonia, generalized infection, or severe trauma to the lungs, but
      can also be less commonly caused by smoke or salt water inhalation, drug overdose, or shock.

      For some people, ALI/ARDS resolves without treatment, but many severe cases result in
      hospitalization in the intensive care unit (ICU), where 30% to 40% of cases end in mortality.
      Current treatments for ALI/ARDS include assisted breathing with a ventilator, supportive
      care, and management of the underlying causes.

      Upon admission to the ICU, Rosuvastatin or placebo was administered through an enteral
      feeding tube or administered orally following extubation when patients were able to safely
      take oral medications. The type and placement of the enteral feeding tube (nasogastric,
      nasoenteric, PEG, orogastric, oroenteric, etc.) and the ability to safely take oral
      medications was determined by the patient's primary team. Study drug was blinded with an
      identical appearing placebo. The first study drug dose (rosuvastatin or placebo) was
      administered within 4 hours of randomization as a loading dose of 40 mg.

      Blood pressure, heart rate, ventilation settings, and various blood factors were measured
      during treatment. Phone-based follow-up assessments occurred at months 6 and 12 after ICU
      discharge and included measurements of health-related quality of life; psychological,
      neurocognitive, and physical activity outcomes; healthcare utilization; and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    stopped for futility
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Mortality to Day 60.</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>The percentage of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days at Study Day 28</measure>
    <time_frame>time of initiating unassisted breathing to day 28 after study randomization</time_frame>
    <description>Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Organ Failure Free Days at Day 14</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>The number of days from randomization to day 14 without an organ failure. Four main organ systems were measured: cardiovascular, coagulation, hepatic function, and renal function.</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU Free Days to Day 28</measure>
    <time_frame>28 days after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other Secondary Out-comes</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Percentage of subjects with Arrhythmia's, Bowel Ischemia, Myocardial Infarction, Ischemic Stroke, and Thromboembolism were measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Plasma Concentrations of C-reactive Protein (CRP) From Baseline to Day 6 and Day 14</measure>
    <time_frame>6 and 14 days after randomization</time_frame>
    <description>CRP levels were collected on subjects at baseline and on-study. The change in concentration from baseline levels to levels on study days 6 and 14 was analyzed. Those subjects that were still alive and on study at day 6 and 14 with a measured CRP level were included in the analysis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>Sepsis</condition>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects were randomized to the active drug (Rosuvastatin).
Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.
Duration: drug was administered daily until:
28 days after randomization or 3 days after ICU discharge (whichever comes first),
Discharge from study hospital,
Death</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the subjects were randomized to placebo.
10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Systemic inflammatory response syndrome (SIRS) defined as meeting at least criteria
             (a) or (b)for a systemic inflammatory response:

               1. White blood cell count &gt;12,000 or &lt;4,000 or &gt;10% band forms

               2. Body temperature &gt;38 degrees Celsius (C) (any route) or &lt;36 degrees C (accepting
                  core temperatures only; indwelling catheter, esophageal, rectal)

               3. Heart rate (&gt; 90 beats/min) or receiving medications that slow heart rate or
                  paced rhythm 2. Suspected or proven infection: Sites of infection include thorax,
                  urinary tract, abdomen, skin, sinuses, central venous catheters, and bacterial
                  meningitis (Appendix A).

                  3. ALI as defined by acute onset of:

               1. PaO2 / FiO2 ≤ 300 (intubated). If altitude &gt; 1000m, then PaO2 / FiO2 ≤ 300 x
                  (PB/760), and

               2. Bilateral infiltrates consistent with pulmonary edema on frontal chest
                  radiograph, and

               3. Requirement for positive pressure ventilation via an endotracheal tube, and

               4. No clinical evidence of left atrial hypertension, or if measured, a Pulmonary
                  Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg. If a patient has a
                  PAOP &gt; 18 mmHg, then the other criteria must persist for more than 12 hours after
                  the PAOP has declined to ≤ 18 mmHg, and still be within the 48-hour enrollment
                  window.

        &quot;Acute onset&quot; is defined as follows: the duration of the hypoxemia criterion (#1) and the
        chest radiograph criterion (#2) must be ≤ 28 days at the time of randomization. Opacities
        considered &quot;consistent with pulmonary edema&quot; include any patchy or diffuse opacities not
        fully explained by mass, atelectasis, or effusion or opacities known to be chronic (&gt; 28
        days). The findings of vascular redistribution, indistinct vessels, and indistinct cardiac
        borders are not considered &quot;consistent with pulmonary edema&quot;.

        All ALI criteria (3a-d above) must occur within the same 24 hour period. The onset of ALI
        is when the last ALI criterion is met. Patients must be enrolled within 48 hours of ALI
        onset and no more than 7 days from the initiation of mechanical ventilation. SIRS criteria
        must occur within the 72 hours before or the 24 hours after ALI onset. Information for
        determining when these time window criteria were met may come from either the Network
        hospital or a referring hospital reports.

        Exclusion Criteria:

          1. No consent/inability to obtain consent

          2. Age less than 18 years

          3. More than 7 days since initiation of mechanical ventilation

          4. More than 48 hours since meeting ALI inclusion criteria

          5. Patient, surrogate, or physician not committed to full support ).

          6. Unable to receive or unlikely to absorb enteral study drug

          7. Rosuvastatin specific exclusions

               -  Receiving a statin medication within 48 hours of randomization

               -  Allergy or intolerance to statins

               -  Physician insistence for the use or avoidance of statins during the current
                  hospitalization

               -  Creatine Kinase (CK) , alanine aminotransferase (ALT) or aspartate
                  aminotransferase (AST) &gt; 5 times the upper limit of normal

               -  Diagnosis of hypothyroidism and not on thyroid replacement therapy

               -  Pregnancy or breast feeding

               -  Receiving niacin, fenofibrate or cyclosporine, gemfibrozil, atazanavir,
                  lopinavir, ritonavir, daptomycin

          8. Severe chronic liver disease

          9. Moribund patient not expected to survive 24 hours

         10. Chronic respiratory failure defined as PaCO2 &gt; 60 mm Hg in the outpatient setting

         11. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for
             CPAP/BIPAP (Continuous Positive Airway Pressure/BiLevel Positive Airway Pressure) used
             solely for sleep-disordered breathing

         12. Diffuse alveolar hemorrhage from vasculitis

         13. Burns &gt; 40% total body surface

         14. Interstitial lung disease of severity sufficient to require continuous home oxygen
             therapy

         15. Unwillingness or inability to utilize the ARDS network 6 ml/kg Predicted Body Weight
             (PBW) ventilation protocol

         16. Cardiac disease classified as NYHA (New York Heart Association) class IV

         17. Myocardial infarction within past 6 months

         18. Intraparenchymal Central Nervous System (CNS) bleed within a month of randomization.

         19. Temperature &gt;40.3 C in the 6 hours before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathon Truwit, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia, Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of San Francisco-Fresno Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF-Moffitt Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF)-Moffitt Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centura St. Anthony Central Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Hospital-Blue Bonnet</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Hospital-Midcity</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Earl K. Long Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Louisiana</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Methodist Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital, Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Regional Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone Health System</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Long Community Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay-Dee Hospital</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ardsnet.org</url>
    <description>ARDS Network Website</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <results_first_submitted>August 22, 2014</results_first_submitted>
  <results_first_submitted_qc>October 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2014</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALI</keyword>
  <keyword>Sepsis</keyword>
  <keyword>statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>ARDSNet-SAILS</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/sails/</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/sails/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Forms</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/sails/</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin</title>
          <description>Half of the subjects will receive the active drug, Rosuvastatin.
Rosuvastatin: Patients will receive 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Half of the patients will be randomized to the placebo.
Placebo: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study hospital.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="366"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="366"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin</title>
          <description>Half of the subjects will receive the active drug, Rosuvastatin.
Rosuvastatin: Patients will receive 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Half of the patients will be randomized to the placebo.
Placebo: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study hospital.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="379"/>
            <count group_id="B2" value="366"/>
            <count group_id="B3" value="745"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="17.1"/>
                    <measurement group_id="B2" value="54.1" spread="15.6"/>
                    <measurement group_id="B3" value="54.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">not captured</measurement>
                    <measurement group_id="B2" value="NA">not captured</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APACHE III Score</title>
          <description>APACHE III Score: Acute, Physiology, Age, Chronic Health Evaluation III Prognostic System is a measure of hospital mortality risk for critically ill adult patients. Our study used a refined version based on the study by Knause and colleagues (Chest, 1991; 100:1619-36). The score is based on results from addition of 3 groups of variables (physiology, range: 0-252; age: 0-23; and chronic health: 0-24). Overall score range: 0-299; higher number indicates higher risk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.1" spread="28.4"/>
                    <measurement group_id="B2" value="94.8" spread="27.9"/>
                    <measurement group_id="B3" value="93.4" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary cause of lung injury</title>
          <description>Based on coding of primary vs. secondary by the site; data entry errors account for total count discrepancy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Aspiration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trauma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Shock</title>
          <description>The number of participants who were in shock at the time of randomization. Baseline shock was defined as meeting one of the following conditions: a mean arterial pressure less than 60 mm Hg, receiving a vasopressor (norepinephrine, epinephrine, vasopressin or neosynephrine) at any dose, or receiving dopamine at a dose greater than or equal to 6 mcg/kg/min (or mcg/min) .</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PaFiO2:FiO2 ratio less than or equal to 200 mm Hg</title>
          <description>The number of participants with a P/F ratio of 200 mm Hg or less at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hours from intubation to randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>24 hours or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>between 24 and 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>between 48 and 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>more than 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Mortality to Day 60.</title>
        <description>The percentage of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.</description>
        <time_frame>60 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Half of the subjects were randomized to active drug (Rosuvastatin).
Rosuvastatin: Subjects received 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharge from the study hospital.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Half of the subjects were randomized to placebo.
Placebo: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharge from study hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality to Day 60.</title>
          <description>The percentage of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="24.0" upper_limit="33.0"/>
                    <measurement group_id="O2" value="24.9" lower_limit="20.5" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospital mortality to day 60 was estimated using the Kaplan Meier estimate, with patients discharged home before day 60 considered alive at day 60. The analysis was stratified by co-enrolled treatment assignments for 81 patients also enrolled in a randomized clinical trial of two different nutritional strategies. A maximum of 1000 patients were to be enrolled, providing a 92% probability of rejecting the null hypothesis for the effect on mortality if a true difference in mortality was 9%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>The monitoring boundaries were designed to have a low probability of stopping for futility before 750 patients. The maximum sample size was 1000 patients. Efficacy stopping was based on mortality; futility stopping was based on mortality and VFDs.</p_value_desc>
            <method>Proc lifetest</method>
            <method_desc>Proc lifetest was used to calculate mortality mean and variance due to one subject lost to follow up who was censored.</method_desc>
            <param_type>difference in % of pts alive at 60 days</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Free Days at Study Day 28</title>
        <description>Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.</description>
        <time_frame>time of initiating unassisted breathing to day 28 after study randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Half of the subjects were randomized to active drug (Rosuvastatin).
Rosuvastatin: Subjects received 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharge from the study hospital.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Half of the subjects were randomized to placebo.
Placebo: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days at Study Day 28</title>
          <description>Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="10.8"/>
                    <measurement group_id="O2" value="15.1" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator, ICU free, and organ failure free days were analyzed by analysis of variance, utilizing treatment assignment where applicable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Organ Failure Free Days at Day 14</title>
        <description>The number of days from randomization to day 14 without an organ failure. Four main organ systems were measured: cardiovascular, coagulation, hepatic function, and renal function.</description>
        <time_frame>14 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Half of the subjects were randomized to active drug (Rosuvastatin).
Rosuvastatin: Patients received 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharge from the study hospital.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Half of the subjects were randomized to placebo.
Placebo: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharge from study hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Organ Failure Free Days at Day 14</title>
          <description>The number of days from randomization to day 14 without an organ failure. Four main organ systems were measured: cardiovascular, coagulation, hepatic function, and renal function.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="4.8"/>
                    <measurement group_id="O2" value="8.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.1"/>
                    <measurement group_id="O2" value="11.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="5.0"/>
                    <measurement group_id="O2" value="11.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="5.3"/>
                    <measurement group_id="O2" value="11.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ICU Free Days to Day 28</title>
        <time_frame>28 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Half of the subjects will receive the active drug, Rosuvastatin.
Rosuvastatin: Patients will receive 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Half of the patients will be randomized to the placebo.
Placebo: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Free Days to Day 28</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="10.1"/>
                    <measurement group_id="O2" value="14.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Other Secondary Out-comes</title>
        <description>Percentage of subjects with Arrhythmia's, Bowel Ischemia, Myocardial Infarction, Ischemic Stroke, and Thromboembolism were measured.</description>
        <time_frame>28 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Half of the subjects were randomized to active drug (Rosuvastatin).
Rosuvastatin: Subjects received 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharge from the study hospital.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Half of the subjects were randomized to placebo.
Placebo: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharge from study hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Out-comes</title>
          <description>Percentage of subjects with Arrhythmia's, Bowel Ischemia, Myocardial Infarction, Ischemic Stroke, and Thromboembolism were measured.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arrhythmias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.1" upper_limit="11.9"/>
                    <measurement group_id="O2" value="8.4" lower_limit="5.5" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.2" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-0.3" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ischemic Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-.03" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-0.3" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="3.8" upper_limit="8.9"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.4" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Plasma Concentrations of C-reactive Protein (CRP) From Baseline to Day 6 and Day 14</title>
        <description>CRP levels were collected on subjects at baseline and on-study. The change in concentration from baseline levels to levels on study days 6 and 14 was analyzed. Those subjects that were still alive and on study at day 6 and 14 with a measured CRP level were included in the analysis.</description>
        <time_frame>6 and 14 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Half of the subjects were randomized to active drug (Rosuvastatin).
Rosuvastatin:Subjects received 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharge from the study hospital.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Half of the subjects were randomized to placebo.
Placebo: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharge from study hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Plasma Concentrations of C-reactive Protein (CRP) From Baseline to Day 6 and Day 14</title>
          <description>CRP levels were collected on subjects at baseline and on-study. The change in concentration from baseline levels to levels on study days 6 and 14 was analyzed. Those subjects that were still alive and on study at day 6 and 14 with a measured CRP level were included in the analysis.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" spread="27.79"/>
                    <measurement group_id="O2" value="-15.1" spread="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" spread="31.23"/>
                    <measurement group_id="O2" value="-14.8" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first.</time_frame>
      <desc>AE definition: any clinically important untoward medical occurrence in a patient receiving study drug/procedures which was different than expected in the clinical course of a patient with ALI or an occurrence thought to be associated with the study drug/procedures. CK, ALT/AST at specified levels and CNS bleed were also systematically reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin</title>
          <description>Half of the subjects were randomized to the active drug (Rosuvastatin).
Rosuvastatin: Subjects received 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharge from the study hospital.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Half of the subjects were randomized to placebo.
Placebo: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharge from study hospital.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Hemorrhage (Nos)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Thrombosis Venous Arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALT &gt; 8 times upper limit of normal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Bowel Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Ischemia Bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Necrosis Bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Obstruction Small Intestine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Peforation Bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage Retroperitoneal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Neuroleptic Malignant Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST &gt; 8 times upper limit of normal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Ast Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Creatinine Serum Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CK &gt; 10 times upper limit of normal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Brain Disorder (Nos)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Intracerebral Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Failure Kidney Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Coughing Blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Embolism Pulmonary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>sponsor can review results communications prior to public release and can embargo communications regarding trial results until presented at the American Thoracic Society international meeting.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David A. Schoenfeld, PhD ARDSNet CCC PI</name_or_title>
      <organization>ARDS Network</organization>
      <phone>617-726-6111</phone>
      <email>dschoenfeld@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

